Michelle Petri

Professor

1985 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 5 Similar Profiles
Systemic Lupus Erythematosus Medicine & Life Sciences
Lupus Nephritis Medicine & Life Sciences
Antiphospholipid Antibodies Medicine & Life Sciences
Antiphospholipid Syndrome Medicine & Life Sciences
Pregnancy Medicine & Life Sciences
Kidney Medicine & Life Sciences
African Americans Medicine & Life Sciences
Autoantibodies Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1985 2018

A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires

Costedoat-Chalumeau, N. , Houssiau, F. , Izmirly, P. , Le Guern, V. , Navarra, S. , Jolly, M. , Ruiz-Irastorza, G. , Baron, G. , Hachulla, E. , Agmon-Levin, N. , Shoenfeld, Y. , Dall'Ara, F. , Buyon, J. , Deligny, C. , Cervera, R. , Lazaro, E. , Bezanahary, H. , Leroux, G. , Morel, N. , Viallard, J. F. & 11 others Pineau, C., Galicier, L., Van Vollenhoven, R., Tincani, A., Nguyen, H., Gondran, G., Zahr, N., Pouchot, J., Piette, J. C., Petri, M. & Isenberg, D., Jun 1 2018, In : Clinical Pharmacology and Therapeutics. 103, 6, p. 1074-1082 9 p.

Research output: Contribution to journalArticle

Prospective Studies
Hydroxychloroquine
Pharmaceutical Preparations
Tablets
Physicians

Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis

Hardt, U., Larsson, A., Gunnarsson, I., Clancy, R. M., Petri, M., Buyon, J. P., Silverman, G. J., Svenungsson, E. & Grönwall, C., Feb 26 2018, In : Arthritis Research and Therapy. 20, 1, 36

Research output: Contribution to journalArticle

Nephritis
Malondialdehyde
Systemic Lupus Erythematosus
Complement C1q
Inflammation

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Wallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M. A., Dörner, T., Cardiel, M. H., Bruce, I. N., Gomez, E., Carmack, T., DeLozier, A. M., Janes, J. M., Linnik, M. D., de Bono, S., Silk, M. E. & Hoffman, R. W., Jul 21 2018, In : The Lancet. 392, 10143, p. 222-231 10 p.

Research output: Contribution to journalArticle

Systemic Lupus Erythematosus
Placebos
baricitinib
Exanthema
Arthritis

Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment

Chan, K., Clarke, A. E., Ramsey-Goldman, R., Foulkes, W., Tessier Cloutier, B., Urowitz, M. B., Gladman, D., Nived, O., Romero-Diaz, J., Petri, M., Ginzler, E., Fortin, P. R., Bae, S. C., Wallace, D. J., Yelin, E. H. & Bernatsky, S., Jan 1 2018, In : Lupus. 27, 1, p. 120-123 4 p.

Research output: Contribution to journalArticle

Systemic Lupus Erythematosus
Progesterone
Estrogens
Estrogen Receptors
Breast Neoplasms

Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index

Kalunian, K. C., Urowitz, M. B., Isenberg, D., Merrill, J. T., Petri, M., Furie, R. A., Morgan-Cox, M. A., Taha, R., Watts, S., Silk, M. & Linnik, M. D., Jan 1 2018, In : Rheumatology (Oxford, England). 57, 1, p. 125-133 9 p.

Research output: Contribution to journalArticle

Systemic Lupus Erythematosus
Medication Adherence
Clinical Trials
Adrenal Cortex Hormones
Alopecia